Woodland International Research Group

Summary

Woodland International Research Group is a medical facility located in Little Rock, Arkansas. This center is recognized for care of Schizophrenia, Major Depressive Disorder, Depression, Bipolar Disorder, Mania and other specialties. Woodland International Research Group is involved with conducting 104 clinical trials across 93 conditions. There are 2 research doctors associated with this hospital, such as George Konis, MD and Konis.

Top PIs

Clinical Trials running at Woodland International Research Group

Schizophrenia

Mania

Bipolar disorder

I Am A Healthy Volunteer

Coronavirus

COVID-19

Alcohol-Related Intimate Partner Violence

Alcoholism

Cognitive Impairment

KarXT

for Schizophrenia

This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.

Recruiting

2 awards

Phase 3

5 criteria

SEP-363856

for Schizophrenia

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Recruiting

1 award

Phase 3

1 criteria

Emraclidine

for Schizophrenia

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruiting

0 awards

Phase 2

1 criteria